A5083147929- Lung Cancer Treatments and Mutations
- Head and Neck Cancer Studies
- Lung Cancer Research Studies
- Lymphoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- HER2/EGFR in Cancer Research
- Viral-associated cancers and disorders
- Lung Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Head and Neck Surgical Oncology
- Renal cell carcinoma treatment
- Nutrition and Health in Aging
- Advanced Radiotherapy Techniques
- Cancer Research and Treatments
- Cancer Genomics and Diagnostics
- Esophageal Cancer Research and Treatment
- Retinal Diseases and Treatments
- Virus-based gene therapy research
- Erythropoietin and Anemia Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Parathyroid Disorders and Treatments
- Peptidase Inhibition and Analysis
- Sarcoma Diagnosis and Treatment
Soochow University
2024-2025
The First People's Hospital of Changzhou
2025
People's Hospital of Cangzhou
2025
Peking University
2014-2024
Peking University Cancer Hospital
2014-2024
Hangzhou Medical College
2024
Zhejiang Provincial People's Hospital
2024
Changzhou No.2 People's Hospital
2024
Guangzhou Medical University
2024
Hunan Cancer Hospital
2024
Platinum-based concurrent chemoradiotherapy is the standard of care for patients with locoregionally advanced nasopharyngeal carcinoma. Additional gemcitabine and cisplatin induction chemotherapy has shown promising efficacy in phase 2 trials.
Neratinib is an oral, irreversible pan-ErbB receptor tyrosine kinase inhibitor. The efficacy and safety of neratinib were evaluated in two cohorts patients with advanced ErbB2-positive breast cancer-those those without prior trastuzumab treatment-in open-label, multicenter, phase II trial.Patients the (prior trastuzumab, n = 66; no 70) received oral 240 mg once daily. primary end point was 16-week progression-free survival (PFS) rate for evaluable population 63; 64), as assessed by...
<h3>Importance</h3> Secondary hyperparathyroidism contributes to extraskeletal calcification and is associated with all-cause cardiovascular mortality. Control suboptimal in the majority of patients receiving hemodialysis. An intravenously (IV) administered calcimimetic could improve adherence reduce adverse gastrointestinal effects. <h3>Objective</h3> To evaluate relative efficacy safety IV etelcalcetide oral cinacalcet. <h3>Design, Setting, Participants</h3> A randomized, double-blind,...
Recent data showed improvement in progression-free survival (PFS) when adding everolimus to exemestane patients with advanced breast cancer experiencing recurrence/progression after nonsteroidal aromatase inhibitor (AI) therapy. Here, we report clinical outcomes of combining the mammalian target rapamycin (mTOR) temsirolimus letrozole AI-naive patients.This phase III randomized placebo-controlled study tested efficacy/safety first-line oral 2.5 mg daily/temsirolimus 30 daily (5 days every 2...
To report long‐term results of a randomized controlled trial that compared cisplatin/fluorouracil/docetaxel (TPF) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) with CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC). Patients stage III–IVB (except T3–4 N0) NPC were randomly assigned to receive IC (n = 241) or 239). included three cycles docetaxel (60 mg/m 2 d1), cisplatin and fluorouracil (600 /d civ d1–5) every 3 weeks. from both groups received...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically on the based primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported.We previously reported significantly improved failure-free survival using gemcitabine plus cisplatin induction...
Substantial evidence suggests that anemia is an independent risk factor for worse outcomes in patients with heart failure (HF). The Study of Anemia Heart Failure Trial (STAMINA-HeFT) the largest multicenter, randomized, double-blind, placebo-controlled trial to date evaluating effect treating HF.Patients (N=319) symptomatic HF, left ventricular ejection fraction < or = 40%, and hemoglobin > 9.0 g/dL 12.5 were randomized (double-blind) placebo (N=157) darbepoetin alfa (N=162) subcutaneously...
Purpose. This phase II, open-label, multicenter study assessed the oral, multitargeted, tyrosine kinase inhibitor sunitinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma who had received prior chemotherapy. Experimental design. Patients 50 mg/day on Schedule 4/2 (4 weeks treatment, followed by 2 off treatment). The primary endpoint was objective response rate; secondary endpoints included clinical benefit rate, duration of response, progression-free survival...
Purpose This double-blind, phase III study aimed to demonstrate that sunitinib plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior placebo in previously untreated metastatic colorectal cancer (mCRC). Patients Methods were randomly assigned receive either (37.5 mg per day) or (4 weeks on treatment, followed by 2 off [schedule 4/2]) until disease progression. The primary end point progression-free survival (PFS). Secondary points included overall survival, safety,...
Background This study aimed to evaluate the antitumor activity of camrelizumab, an antiprogrammed cell death-1 antibody, in pretreated recurrent or metastatic nasopharyngeal carcinoma (NPC) and explore predictive biomarkers. Methods Patients with (not amenable locally curative treatment) NPC who had failed at least two lines chemotherapy were eligible receive camrelizumab (200 mg intravenously every 2 weeks) for years until disease progression, intolerable adverse events, withdrawal...
Purpose To centrally assess the safety, efficacy, and 6-year follow-up of recombinant adenovirus-p53 (rAd-p53) combined with radiotherapy (RT) for patients nasopharyngeal carcinoma (NPC). Patients Methods A randomized controlled clinical study on rAd-p53 RT in 42 NPC was compared a control group 40 treated alone. In receiving RT, intratumorally injected once week 8 weeks. Concurrent (70 Gy 35 fractions) given to tumor neck lymph node. tumors were monitored adverse events responses. Results...